Health, Heart Disease
Conditions
Keywords
children with heart disease, infants, healthy newborns
Brief summary
B-type natriuretic Peptide (BNP) is a cardiac hormone secreted from the cardiac myocytes in response to volume load. Plasma levels of BNP, as measured by immunoassay methods, are elevated in patients with heart diseases. However, the biological effects of BNP are blunted in heart failure and other cardiac conditions. Moreover, the peptide levels are also elevated in non cardiac conditions such as the neonatal period, sepsis and renal failure. Recent investigations suggest alteration of the peptide molecular structure in heart failure. These alterations may explain, at least partially, the reduced biological activities of BNP in heart failure. Immunoreactive BNP and NT-proBNP have been identified in human urine. It has been suggested that urinary BNP correlates with plasma BNP, and may serve as a non-invasive measure for this cardiac marker. It is unclear what BNP fractions are cleared in the urine in health and disease. The aim of the proposed studies is to elucidate precisely the molecular form of BNP in various disease and specific physiological states in plasma and urine of infants and children.
Interventions
OTHERno intervention
Sponsors
Hadassah Medical Organization
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy newborn infants with normal pregnancy and delivery 2. Premature infants 3. Infants and children with heart disease who have NT-proBNP levels taken as part of cardiac evaluation
Exclusion criteria
1. Patients with non cardiac disease (renal, hepatic) 2. Patients with acute urinary disease or other acute non-cardiac diseases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| molecular forms of BNP in healthy newborns, infants and children with heart disease. | one year | Quantification of the specific molecular forms will be performed by liquid chromatography coupled to mass spectrometry. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| BNP presence and define its molecular forms in urine of healthy newborns,infants and children with heart disease. BNP presence and define its molecular forms in urine of healthy newborns and infant and children with heart disease. BNP presence and | one year | Quantification of the specific molecular forms will be performed by liquid chromatography coupled to mass spectrometry. |
Countries
Israel
Outcome results
None listed